

World Journal of *Clinical Cases*

World J Clin Cases 2022 January 7; 10(1): 1-396



MINIREVIEWS

- 1 Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance
Ren SY, Wang WB, Gao RD, Zhou AM
- 12 Hepatitis B virus reactivation in rheumatoid arthritis
Wu YL, Ke J, Zhang BY, Zhao D
- 23 Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential
Huang F, Chen WY, Ma J, He XL, Wang JW

ORIGINAL ARTICLE

Case Control Study

- 35 Changes in rheumatoid arthritis under ultrasound before and after sinomenine injection
Huang YM, Zhuang Y, Tan ZM
- 43 Benefits of multidisciplinary collaborative care team-based nursing services in treating pressure injury wounds in cerebral infarction patients
Gu YH, Wang X, Sun SS

Retrospective Study

- 51 Outcomes and complications of open, laparoscopic, and hybrid giant ventral hernia repair
Yang S, Wang MG, Nie YS, Zhao XF, Liu J
- 62 Surgical resection of intradural extramedullary tumors in the atlantoaxial spine *via* a posterior approach
Meng DH, Wang JQ, Yang KX, Chen WY, Pan C, Jiang H
- 71 Vancomycin lavage for the incidence of acute surgical site infection following primary total hip arthroplasty and total knee arthroplasty
Duan MY, Zhang HZ
- 79 Distribution of transient receptor potential vanilloid-1 channels in gastrointestinal tract of patients with morbid obesity
Atas U, Erin N, Tazegul G, Elpek GO, Yıldırım B
- 91 Value of neutrophil-lymphocyte ratio in evaluating response to percutaneous catheter drainage in patients with acute pancreatitis
Gupta P, Das GC, Bansal A, Samanta J, Mandavdhare HS, Sharma V, Naseem S, Gupta V, Yadav TD, Dutta U, Varma N, Sandhu MS, Kochhar R

- 104** Influence of overweight and obesity on the mortality of hospitalized patients with community-acquired pneumonia
Wang N, Liu BW, Ma CM, Yan Y, Su QW, Yin FZ
- 117** Minimally invasive open reduction of greater tuberosity fractures by a modified suture bridge procedure
Kong LP, Yang JJ, Wang F, Liu FX, Yang YL
- 128** Increased levels of lactate dehydrogenase and hypertension are associated with severe illness of COVID-19
Jin ZM, Shi JC, Zheng M, Chen QL, Zhou YY, Cheng F, Cai J, Jiang XG
- 136** Age, alcohol, sex, and metabolic factors as risk factors for colonic diverticulosis
Yan Y, Wu JS, Pan S
- 143** Evaluation of right-to-left shunt on contrast-enhanced transcranial Doppler in patent foramen ovale-related cryptogenic stroke: Research based on imaging
Xiao L, Yan YH, Ding YF, Liu M, Kong LJ, Hu CH, Hui PJ
- 155** Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters
Lee H, Chung YS, Lee JH, Lee KY, Hwang KH

Clinical Trials Study

- 166** Low-dose intralesional injection of 5-fluorouracil and triamcinolone reduces tissue resident memory T cells in chronic eczema
Wu Y, Wang GJ, He HQ, Qin HH, Shen WT, Yu Y, Zhang X, Zhou ML, Fei JB

Observational Study

- 177** Alterations in blink and masseter reflex latencies in older adults with neurocognitive disorder and/or diabetes mellitus
Bricio-Barrios JA, Rios-Bracamontes E, Rios-Silva M, Huerta M, Serrano-Moreno W, Barrios-Navarro JE, Ortiz GG, Huerta-Trujillo M, Guzmán-Esquivel J, Trujillo X
- 189** Predicting adolescent perfectionism: The role of socio-demographic traits, personal relationships, and media
Livazović G, Kuzmanović K
- 205** Novel m.4268T>C mutation in the mitochondrial tRNA^{Leu} gene is associated with hearing loss in two Chinese families
Zhao LJ, Zhang ZL, Fu Y
- 217** Superior mesenteric venous thrombosis: Endovascular management and outcomes
Alnahhal K, Toskich BB, Nussbaum S, Li Z, Erben Y, Hakaim AG, Farres H

Randomized Controlled Trial

- 227** Zinc carnosine-based modified bismuth quadruple therapy *vs* standard triple therapy for *Helicobacter pylori* eradication: A randomized controlled study
Ibrahim N, El Said H, Choukair A

CASE REPORT

- 236 Acquired coagulation dysfunction resulting from vitamin K-dependent coagulation factor deficiency associated with rheumatoid arthritis: A case report
Huang YJ, Han L, Li J, Chen C
- 242 Intraoperative thromboelastography-guided transfusion in a patient with factor XI deficiency: A case report
Guo WJ, Chen WY, Yu XR, Shen L, Huang YG
- 249 Positron emission tomography and magnetic resonance imaging combined with computed tomography in tumor volume delineation: A case report
Zhou QP, Zhao YH, Gao L
- 254 Successful response to camrelizumab in metastatic bladder cancer: A case report
Xie C, Yuan X, Chen SH, Liu ZY, Lu DL, Xu F, Chen ZQ, Zhong XM
- 260 HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
Wang L, Jiang Q, He MY, Shen P
- 268 Hyper-accuracy three-dimensional reconstruction as a tool for better planning of retroperitoneal liposarcoma resection: A case report
Ye MS, Wu HK, Qin XZ, Luo F, Li Z
- 275 Recurrent postmenopausal bleeding - just endometrial disease or ovarian sex cord-stromal tumor? A case report
Wang J, Yang Q, Zhang NN, Wang DD
- 283 Complex proximal femoral fracture in a young patient followed up for 3 years: A case report
Li ZY, Cheng WD, Qi L, Yu SS, Jing JH
- 289 Bilateral Hypertrophic Olivary Degeneration after Pontine Hemorrhage: A Case Report
Zheng B, Wang J, Huang XQ, Chen Z, Gu GF, Luo XJ
- 296 Clinical characteristics and outcomes of primary intracranial alveolar soft-part sarcoma: A case report
Chen JY, Cen B, Hu F, Qiu Y, Xiao GM, Zhou JG, Zhang FC
- 304 Removal of laparoscopic cerclage stitches *via* laparotomy and rivanol-induced labour: A case report and literature review
Na XN, Cai BS
- 309 Cerebral venous sinus thrombosis in pregnancy: A case report
Zhou B, Huang SS, Huang C, Liu SY
- 316 Eustachian tube teratoma: A case report
Li JY, Sun LX, Hu N, Song GS, Dou WQ, Gong RZ, Li CT

- 323** Protein-losing enteropathy caused by a jejunal ulcer after an internal hernia in Petersen's space: A case report
Yasuda T, Sakurazawa N, Kuge K, Omori J, Arai H, Kakinuma D, Watanabe M, Suzuki H, Iwakiri K, Yoshida H
- 331** Lunate dislocation with avulsed triquetral fracture: A case report
Li LY, Lin CJ, Ko CY
- 338** Clinical manifestations and prenatal diagnosis of Ullrich congenital muscular dystrophy: A case report
Hu J, Chen YH, Fang X, Zhou Y, Chen F
- 345** Diagnosis and guidance of treatment of breast cancer cutaneous metastases by multiple needle biopsy: A case report
Li ZH, Wang F, Zhang P, Xue P, Zhu SJ
- 353** Test of incremental respiratory endurance as home-based, stand-alone therapy in chronic obstructive pulmonary disease: A case report
Dosbaba F, Hartman M, Batalik L, Brat K, Plutinsky M, Hnatiak J, Formiga MF, Cahalin LP
- 361** Diagnostic and surgical challenges of progressive neck and upper back painless masses in Madelung's disease: A case report and review of literature
Yan YJ, Zhou SQ, Li CQ, Ruan Y
- 371** Suspected cerebrovascular air embolism during endoscopic esophageal varices ligation under sedation with fatal outcome: A case report
Zhang CMJ, Wang X
- 381** An atypical primary malignant melanoma arising from the cervical nerve root: A case report and review of literature
Shi YF, Chen YQ, Chen HF, Hu X
- 388** Epidural blood patch for spontaneous intracranial hypotension with subdural hematoma: A case report and review of literature
Choi SH, Lee YY, Kim WJ

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Ravi Kant, MD, Associate Professor, Division of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina/Anmed Campus, Anderson, SC 29621, United States. rkant82@hotmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Lin-YuTong Wang; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lai Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Bao-Gan Peng

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

January 7, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review

Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen

ORCID number: Luo Wang 0000-0001-8837-9606; Qi Jiang 0000-0001-7236-1014; Meng-Ye He 0000-0003-0567-0399; Peng Shen 0000-0002-1123-9848.

Author contributions: Wang L and Jiang Q contributed equally to this work; all authors have read and approved the final manuscript.

Informed consent statement: The participant in this study provided written informed consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that there are no any conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Country/Territory of origin: China

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

Corresponding author: Peng Shen, MD, Doctor, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. shenp@zju.edu.cn

Abstract

BACKGROUND

As the most common cancer in women, breast cancer is the leading cause of death. Most patients are initially diagnosed as stage I-III. Among those without distant metastases, 64% are local tumors and 27% are regional tumors. Patients in stage IIA-IIIC and those who meet the breast-conserving criterion with the exception of tumor size can consider neoadjuvant chemotherapy (NACT). It is worth noting that the status of tumor cell biomarkers is not consistently static. Endocrine-related estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) encoded by erythroblastic leukemia viral oncogene homolog 2 gene can all alter from positive to negative or *vice versa*, especially in luminal B subtype after NACT. In addition, determination of HER2 status currently mainly relies on immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH), but FISH is commonly used when the result of IHC is uncertain. HER2 is regarded as negative when the IHC result is 0/1+ without the addition of FISH. To the best of our knowledge, this is the first report of a case harboring HER2 status transformation and IHC1+ with positive amplification by FISH after NACT.

CASE SUMMARY

A 49-year-old woman discovered a mass in her right breast and underwent diagnostic workup. Biopsies of the right breast lesion and axillary lymph nodes were obtained. The results pointed to invasive ductal carcinoma with the IHC result for ER (80%), PR (60%), Ki-67 (20%) and ambiguous expression of HER2 (IHC 2+) with negative amplification by FISH (HER2/CEP17 ratio of 1.13). She underwent surgery after NACT. The pathological findings of the surgically resected sample supported invasive ductal carcinoma with the tumor measuring 1.1 cm × 0.8 cm × 0.5 cm and had spread to one of fifteen dissected lymph nodes. Retesting of the specimen showed that the tumor was positive for ER (2+, 85%) and PR (2+, 10%) but negative for HER2 by IHC (1+). Also Ki-67 had dropped to

Grade C (Good): C
 Grade D (Fair): 0
 Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Received: February 28, 2021

Peer-review started: February 28, 2021

First decision: June 7, 2021

Revised: June 10, 2021

Accepted: July 12, 2021

Article in press: July 12, 2021

Published online: January 7, 2022

P-Reviewer: Ni W

S-Editor: Ma YJ

L-Editor: Webster JR

P-Editor: Xing YX



2%. The patient was regularly monitored every 3 mo without evidence of recurrence.

CONCLUSION

Biomarker status should be reassessed after NACT especially in luminal subtypes.

Key Words: Carcinoma; Ductal; Breast; Neoadjuvant therapy; Biomarkers, Tumor; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The precise molecular subtype of breast cancer is helpful in order to develop individualized strategies for systemic treatment; thus, more attention should be paid to the changes in tumor biomarkers before and after surgery. The conversion probability is fairly low, especially regarding HER2 status; however, it directly affects the formulation of adjuvant treatment. Importantly, anti-HER2 therapy has led to a landmark change in patients with HER2 positive breast cancer.

Citation: Wang L, Jiang Q, He MY, Shen P. HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review. *World J Clin Cases* 2022; 10(1): 260-267

URL: <https://www.wjgnet.com/2307-8960/full/v10/i1/260.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i1.260>

INTRODUCTION

As the most common cancer in women, breast cancer is the leading cause of death. Most patients are initially diagnosed as stage I-III. Among those without distant metastases, 64% are local tumors and 27% are regional tumors[1]. Patients in stage IIA-IIIC and those who meet the breast-conserving criterion with the exception of tumor size can consider neoadjuvant chemotherapy (NACT).

It is worth noting that the status of tumor cell biomarkers is not consistently static. Endocrine-related estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) encoded by erythroblastic leukemia viral oncogene homolog 2 gene can all alter from positive to negative or *vice versa*, especially in luminal B subtype after NACT[2]. In addition, determination of HER2 status currently mainly relies on immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH), but FISH is commonly used when the result of IHC is uncertain. HER2 is regarded as negative when the IHC result is 0/1+ without the addition of FISH. To the best of our knowledge, this is the first report of a case harboring HER2 status transformation and IHC1+ with positive amplification by FISH after NACT.

CASE PRESENTATION

Chief complaints

A mass was discovered in the right breast of a 49-year-old woman during a routine examination.

History of present illness

The patient discovered a mass in her right breast and underwent diagnostic workup, including a mammogram which showed a nodule and ultrasound that revealed a mass measuring 2.73 cm × 2.13 cm × 2.57 cm, as well as several enlarged axillary lymph nodes with the largest measuring 1.2 cm × 0.9 cm. Biopsies of the right breast lesion and axillary lymph nodes were obtained. The results pointed to invasive ductal carcinoma with the IHC result for ER (80%), PR (60%), Ki-67 (20%) and ambiguous expression of HER2 (IHC 2+) with negative amplification by FISH (HER2/CEP17 ratio of 1.13) (Figure 1). Computed tomography (CT) of the chest, abdomen, and pelvis




Figure 1 Malignant tumor in the right breast when initially diagnosed. A: Ultrasound showing the mass measuring 2.73 cm × 2.13 cm × 2.57 cm in the 10-o'clock position of the right breast; B: Ultrasound showing the largest right axillary lymph node measuring 1.2 cm × 0.9 cm; C: Hematoxylin-eosin staining indicates an invasive ductal carcinoma (×100); D: Positive control of fluorescence *in situ* hybridization (FISH); E: Negative control of FISH; F: FISH result of the biopsy specimen.

showed no sign of metastatic foci and emission computed tomography (ECT) showed negative results. Accordingly, the patient was classified as stage IIB. The patient received NACT with epirubicin and cyclophosphamide for 4 cycles followed by docetaxel every 3 wk for 4 cycles and she was also supported by long-acting injections to improve the quantity of leukocytes. As a result, the lesion significantly reduced in size and the patient achieved a partial remission according to the RECIST1.1 criteria, and ultrasound showed that the focus had reduced to 0.8 cm × 0.7 cm and no obvious echo of enlarged lymph nodes in the axilla. The patient subsequently underwent lumpectomy of the right breast tumor. Pathological findings of the surgically resected sample supported invasive ductal carcinoma with the tumor measuring 1.1 cm × 0.8 cm × 0.5 cm and had spread to one of fifteen dissected lymph nodes. Retesting of the specimen showed that the tumor was positive for ER (2+, 85%) and PR (2+, 10%) but negative for HER2 by IHC (1+). Also Ki-67 had dropped to 2%. However, HER2 amplified by FISH showed a HER2/CEP17 ratio of 2.46 (Figure 2). The patient completed radiotherapy after surgery. Currently, she is undergoing endocrine treatment with tamoxifen and dual targeted therapy with trastuzumab and pertuzumab. Follow-up which included breast ultrasound, abdominal ultrasound and chest CT were regularly performed every 3 mo without evidence of recurrence.

History of past illness

The patient was healthy without a history of chronic disease or other breast diseases.

Physical examination

A movable mass measuring approximately 2.7 cm × 2.0 cm × 2.5 cm in the right breast and an ipsilateral enlarged axillary lymph node measuring 1.2 cm × 1.0 cm were identified. There was no evidence of disease in the contralateral breast and axillary lymph node.

Laboratory examinations

All laboratory examinations were in the normal range.

Imaging examinations

A mammogram showed a nodule and ultrasound revealed a mass measuring 2.73 cm × 2.13 cm × 2.57 cm, as well as several enlarged axillary lymph nodes with the largest measuring 1.2 cm × 0.9 cm. CT of the chest, abdomen, and pelvis showed no sign of metastatic foci and ECT showed negative results.




Figure 2 Ultrasound result after neoadjuvant chemotherapy and histopathological and fluorescence *in situ* hybridization findings of the resected tumor. A: Ultrasound demonstrating the tumor measuring 0.8 cm × 0.7 cm after neoadjuvant chemotherapy (arrow); B: Histopathological finding showing the tumor cells tubular arrangement and the development of invasion (H&E staining, × 50) (arrow); C: Positive control of fluorescence in situ hybridization (FISH); D: Negative control of FISH; E: FISH result of the surgically resected tumor.

FINAL DIAGNOSIS

The patient was diagnosed with HER2-positive and hormone receptor-positive invasive ductal carcinoma.

TREATMENT

Epirubicin and cyclophosphamide for 4 cycles followed by docetaxel every 3 wk for 4 cycles and then surgery.

OUTCOME AND FOLLOW-UP

Follow-up including breast ultrasound, abdominal ultrasound and chest CT were regularly performed every 3 mo without evidence of recurrence.

DISCUSSION

It has been several years since NACT was recommended for invasive breast cancer patients by the National Comprehensive Cancer Network guidelines. Compared with postoperative adjuvant chemotherapy, NACT not only has the advantage of downgrading the clinical stage to make lumpectomy available for some patients, it also helps to eliminate micro-metastases. In addition, NACT also provides a novel, rapid and low-cost way to evaluate the effectiveness of systemic treatment. In contrast, observation of the efficacy of postoperative adjuvant therapy requires more time, energy and labor. With the popularization of NACT in locally advanced breast cancer, we have compiled the results over the past ten years (Table 1) and found that, compared with the biomarkers in samples obtained by fine needle aspiration or hollow needle biopsy before surgery, postoperative tissue receptors can occasionally produce completely opposite conclusions. The average conversion rate of ER is 7.3%, PR is 15.0% while HER2 is only 6.8% which is consistent with previous data, that is, the status of PR is most inclined to change while HER2 is relatively more stable[3].

Table 1 Status of biomarkers before neoadjuvant chemotherapy and after neoadjuvant chemotherapy

Ref.	Year	Total patients (n)	Frequency of ER alternation, n (%)				Frequency of PR alternation, n (%)				Frequency of Her-2 alternation, n (%)				Frequency of Ki-67 alternation, n (%)			
			P × P	P × N	N × P	N × N	P × P	P × N	N × P	N × N	P × P	P × N	N × P	N × N	P × P	P × N	N × P	N × N
Li <i>et al</i> [12]	2019	565	229 (40.5)	48 (8.5)	53 (9.4)	235 (41.6)	191 (33.8)	76 (13.5)	53 (9.4)	245 (43.4)	439 (39.7)	117 (10.6)	13 (1.2)	536 (48.5)	NA	NA	NA	NA
Peng <i>et al</i> [16]	2019	112	56 (50.0)	18 (16.1)	7 (6.2)	31 (27.7)	32 (28.6)	22 (19.6)	10 (9.0)	48 (42.9)	30 (27.8)	17 (15.2)	6 (5.3)	59 (52.7)	43 (38.4)	42 (37.5)	3 (2.7)	24 (21.4)
Ahn <i>et al</i> [2]	2018	442	305 (69.0)	10 (2.3)	8 (1.8)	119 (26.9)	201 (45.5)	65 (14.7)	15 (3.4)	161 (36.4)	109 (24.7)	4 (0.9)	11 (2.5)	318 (71.9)	113 (25.6)	151 (34.2)	12 (2.7)	166 (37.6)
Yang <i>et al</i> [17]	2018	231	173 (74.9)	NA	NA	3 (1.3)	158 (68.4)	NA	NA	18 (7.8)	26 (11.3)	NA	NA	150 (64.9)	128 (55.4)	NA	NA	48 (20.8)
De La Cruz <i>et al</i> [18]	2018	54	19 (35.2)	2 (3.7)	1 (1.9)	9 (16.7)	NA	NA	NA	NA	5 (9.6)	1 (1.9)	24 (44.4)	NA	NA	NA	NA	NA
Yoshida <i>et al</i> [19]	2017	588	NA	NA	NA	NA	NA	NA	NA	NA	66 (11.2)	33 (5.6)	11 (1.9)	478 (81.3)	NA	NA	NA	NA
Xian <i>et al</i> [20]	2017	77	NA	NA	2 (3.0)	NA	NA	NA	2 (3.0)	NA	NA	NA	1 (1.0)	NA	NA	NA	NA	NA
Niikura <i>et al</i> [21]	2016	16580/16515/16271	10474 (63.2)	499 (3.0)	519 (3.1)	5088 (30.7)	6735 (40.8)	1545 (9.4)	766 (4.6)	7469 (45.9)	2210 (13.6)	601 (3.7)	340 (2.1)	9607 (59.0)	NA	NA	NA	NA
Gahlaut <i>et al</i> [22]	2016	133	NA	7 (5.3)	9 (6.8)	NA	NA	13 (9.8)	5 (3.8)	NA	NA	5 (3.8)	2 (1.5)	NA	NA	NA	NA	NA
Lim <i>et al</i> [23]	2016	290	189 (65.2)	23 (7.9)	29 (10.0)	49 (16.9)	NA	NA	NA	NA	65 (22.4)	17 (5.9)	0 (0.0)	208 (71.7)	NA	NA	NA	NA
Parinyanitikul <i>et al</i> [10]	2015	398	188 (47.2)	23 (5.8)	39 (9.8)	148 (37.2)	105 (26.4)	57 (14.3)	28 (7.0)	207 (52.0)	43 (10.8)	29 (7.3)	11 (2.8)	308 (77.4)	NA	NA	NA	NA
Zhou <i>et al</i> [24]	2015	107	66 (61.7)	11 (10.3)	4 (3.7)	31 (29.0)	50 (46.7)	13 (12.1)	13 (12.1)	31 (29.0)	39 (36.4)	3 (2.8)	2 (1.9)	63 (58.9)	NA	NA	NA	NA
Jin <i>et al</i> [25]	2015	423	202 (47.8)	55 (13.0)	23 (5.4)	143 (33.8)	NA	NA	NA	NA	55 (13.0)	27 (6.4)	13 (3.1)	328 (77.5)	NA	NA	NA	NA
Tan <i>et al</i> [26]	2014	267	87 (32.6)	57 (21.3)	27 (10.1)	123 (46.1)	78 (29.2)	33 (12.4)	21 (7.9)	135 (50.6)	NA	NA	NA	NA	NA	NA	NA	NA
Yang <i>et al</i> [27]	2013	113	NA	6 (5.3)	8 (7.1)	NA	NA	8 (7.1)	10 (8.8)	NA	NA	1 (0.9)	1 (0.9)	NA	NA	NA	NA	NA
Cockburn <i>et al</i> [28]	2013	133	67 (50.4)	11 (8.3)	1 (0.8)	54 (40.6)	40 (30.1)	16 (12.0)	8 (6.0)	69 (51.9)	24 (18.0)	9 (6.8)	7 (5.3)	93 (69.9)	NA	NA	NA	NA
Lee <i>et al</i> [29]	2013	120	58 (48.3)	11 (9.2)	4 (3.3)	47 (39.2)	26 (21.7)	19 (15.8)	3 (2.5)	72 (60.0)	18 (16.8)	6 (5.6)	5 (4.7)	78 (72.9)	NA	NA	NA	NA
Dede <i>et al</i> [30]	2013	63	29 (46.0)	2 (3.2)	0 (0.0)	4 (6.3)	17 (27.0)	7 (11.1)	3 (4.8)	6 (9.5)	NA	NA	NA	NA	NA	NA	NA	NA
Kumaki <i>et al</i> [31]	2011	53	30 (56.7)	3 (5.7)	2 (3.8)	18 (34.0)	15 (28.3)	4 (7.5)	3 (5.7)	31 (58.5)	9 (18.4)	5 (10.2)	0 (0.0)	35 (71.4)	NA	NA	NA	NA

ER: Estrogen receptor; PR: Progesterone receptor; P: Positive; N: Negative; NA: Not available.

Before 2010, the status of HER2 was only determined by FISH, and since then, the results of IHC analysis have been combined. According to the ASCO/CAP guidelines, if the IHC result is 3+/-, it can be diagnosed as HER2 positive, and if the IHC result is 0/1+/-, it is regarded as HER2 negative. In an equivocal situation (IHC2+/-), that is, the complete membrane staining of > 10% of tumor cells is weak to moderate intensity, *in situ* hybridization (ISH) must be performed to determine whether HER2 is amplified

or not. Therefore, it is not necessary to supplement FISH to further confirm the status of HER2 in cases with an IHC score of 0 or 1+-. However, as luminal subtypes are more likely to reveal biomarker conversion and limited therapeutic efficiency which is attributed to the decreased expression of Ki-67 in luminal cases after NACT, we chose to perform FISH on the postoperative specimens of this patient. The results suggested that although the IHC score was 1+-, HER2 was actually proved to be amplified. When reviewing previous literature, we found that despite the low positive rate of gene amplification in IHC0/1+- cases, there was always a small discrepancy between IHC and FISH. Only 2% of the gene was amplified in negative (0/1+-) expression cases by FISH among Chinese patients in the study by Shui *et al*[4] and was approximately 4% in other populations[5].

At present, there is no consensus on the mechanism of NACT on HER2 status. Some researchers believe that the small tissue samples obtained by fine needle aspiration are insufficient to represent the phenotypic characteristics of the entire tumor as different molecular expressions may be displayed in specimens. Some studies have taken heterogeneity within the tumor into account. It has been speculated that NACT kills cells that are sensitive to chemotherapy and the remaining cells gradually dominate during the treatment process resulting in a different appearance with subsequent unfavorable characteristics and composition[6]. Another group assumed that a low level of estrogen in the body after NACT down-regulates the expression of ERs in tumor cells[7]. The management of HER2 expression is partly dependent on ER and the status transition also affects each of these parameters[8]. Therefore, NACT indirectly affects the status of HER2. One study has recently discovered that HER2 targeted therapy can also result in differential expression of genes[9]; thus, we predict that NACT can induce subtle changes in gene stability. In addition, it is worth noting that drugs that target cell microtubules such as paclitaxel can lead to polyploidization of cells, that is, all chromosomes multiply, including those that carry HER2. This is followed by increased copy number of the HER2 gene and the outcome is not equal to the actual amplification of HER2, which seems to explain why some patients are resistant to drugs even if the copy number of HER2 increases[10]. Although statistical and staining biases are rare and the criteria for defining IHC ambiguity (IHC 2+-) varies among trials, they should not be ignored. On the contrary, Parinyanitikul *et al* [11] analyzed HER2 mRNA level after treatment and the results indicated that the level of HER2 expression in most patients remained stable.

The prognosis of these receptor discordances after NACT are multifarious. For patients with locally advanced breast cancer, HER2 overexpression is an independent risk factor regarding 5-year disease-free survival (DFS). In the multivariate analysis by Tural *et al*[12], clinical stage of the tumor, transformation of HER2 from positive to negative and triple negative receptor status significantly influenced DFS. Li *et al*[13] included 2847 patients from eight studies and found that patients with hormone receptors (HR) which changed from positive to negative had worse DFS. Moreover, compared with patients who maintained negative HR status after NACT, those with negative HR which changed to positive tended to have longer DFS and overall survival. However, there are a variety of cut-off values to define HR positivity including 1%, 5% and 10% with few employing the Allred score, therefore they came to a contradictory conclusion regarding the prognosis of negative conversion of ER and PR status after NACT[2,14]. We cannot simply attribute this to different definitions as the total number of patients and their characteristics may also play a role. Additionally, the level of the protein encoded by the MKI67 gene (Ki67) is another independent predictive factor. A high Ki-67 index before surgery is associated with achieving a complete clinical response to NACT[15], whereas a high Ki-67 proliferation index in post-NACT samples is related to shorter DFS.

Nowadays, the status of HER2 can easily be influenced due to the combination of NACT and HER2-targeted therapy. Therefore, verification procedures should routinely be performed pre- and post-NACT. The decision whether or not to administer HER2-targeted therapy or endocrine therapy is largely based on the result. The estimation of rates of recurrence and outcome can also be affected. We expect the patient in this report to benefit from the use of trastuzumab and pertuzumab in the days to come.

CONCLUSION

The conversion of the status of biomarkers including ER, PR, HER2 and Ki-67 is important. Reassessment of the status of these biomarkers after NACT is

recommended, especially in patients with luminal subtypes.

REFERENCES

- 1 **DeSantis CE**, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. *CA Cancer J Clin* 2019; **69**: 438-451 [PMID: [31577379](#) DOI: [10.3322/caac.21583](#)]
- 2 **Ahn S**, Kim HJ, Kim M, Chung YR, Kang E, Kim EK, Kim SH, Kim YJ, Kim JH, Kim IA, Park SY. Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. *Cancer Res Treat* 2018; **50**: 1418-1432 [PMID: [29361816](#) DOI: [10.4143/crt.2017.552](#)]
- 3 **Hariri N**, Roma AA, Hasteh F, Walavalkar V, Fadare O. Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change. *Ann Diagn Pathol* 2017; **31**: 14-19 [PMID: [29146052](#) DOI: [10.1016/j.anndiagpath.2017.06.004](#)]
- 4 **Shui R**, Liang X, Li X, Liu Y, Li H, Xu E, Zhang Z, Lian Y, Guo S, Yao M, Yang H, Xu F, Liu J, Guo D, Wang K, Li J, Ma Y, Wang J, Shi J, Bu H, Yang W. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers. *Clin Breast Cancer* 2020; **20**: e65-e74 [PMID: [31669267](#) DOI: [10.1016/j.clbc.2019.07.013](#)]
- 5 **Bahreini F**, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. *Breast Cancer* 2015; **22**: 615-625 [PMID: [24718809](#) DOI: [10.1007/s12282-014-0528-0](#)]
- 6 **Almendo V**, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. *Cell Rep* 2014; **6**: 514-527 [PMID: [24462293](#) DOI: [10.1016/j.celrep.2013.12.041](#)]
- 7 **Bines J**, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1996; **14**: 1718-1729 [PMID: [8622093](#) DOI: [10.1200/JCO.1996.14.5.1718](#)]
- 8 **Dati C**, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. *Oncogene* 1990; **5**: 1001-1006 [PMID: [1973827](#)]
- 9 **Brasó-Maristany F**, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E, Prat A. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nat Commun* 2020; **11**: 385 [PMID: [31959756](#) DOI: [10.1038/s41467-019-14111-3](#)]
- 10 **Valent A**, Penault-Llorca F, Cayre A, Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. *Cancer Genet* 2013; **206**: 37-41 [PMID: [23313108](#) DOI: [10.1016/j.cancergen.2012.12.001](#)]
- 11 **Parinyanitkul N**, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. *Clin Breast Cancer* 2015; **15**: 153-160 [PMID: [25454687](#) DOI: [10.1016/j.clbc.2014.09.006](#)]
- 12 **Tural D**, Karaca M, Zirtiloglu A, M Hacıoglu B, Sendur MA, Ozet A. Receptor discordances after neoadjuvant chemotherapy and their effects on survival. *J BUON* 2019; **24**: 20-25 [PMID: [30941947](#)]
- 13 **Li C**, Fan H, Xiang Q, Xu L, Zhang Z, Liu Q, Zhang T, Ling J, Zhou Y, Zhao X, Cui Y. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2019; **178**: 497-504 [PMID: [31471838](#) DOI: [10.1007/s10549-019-05421-7](#)]
- 14 **Hirata T**, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. *Br J Cancer* 2009; **101**: 1529-1536 [PMID: [19809429](#) DOI: [10.1038/sj.bjc.6605360](#)]
- 15 **Jain P**, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, Choudhary DK, Yadav A, Koyalla VPB, Sharma M, Dash P, Talwar V. Ki-67 Labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. *Jpn J Clin Oncol* 2019; **49**: 329-338 [PMID: [30753543](#) DOI: [10.1093/jjco/hyz012](#)]
- 16 **Peng JH**, Zhang X, Song JL, Ran L, Luo R, Li HY, Wang YH. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. *Medicine (Baltimore)* 2019; **98**: e13554 [PMID: [30633152](#) DOI: [10.1097/MD.00000000000013554](#)]
- 17 **Yang L**, Zhong X, Pu T, Qiu Y, Ye F, Bu H. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. *World J Surg*

- Oncol* 2018; **16**: 51 [PMID: [29514654](#) DOI: [10.1186/s12957-018-1332-7](#)]
- 18 **De La Cruz LM**, Harhay MO, Zhang P, Ugras S. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? *Ann Surg Oncol* 2018; **25**: 3535-3540 [PMID: [29981025](#) DOI: [10.1245/s10434-018-6608-1](#)]
 - 19 **Yoshida A**, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. *J Surg Oncol* 2017; **116**: 1021-1028 [PMID: [28767137](#) DOI: [10.1002/jso.24762](#)]
 - 20 **Xian Z**, Quinones AK, Tozbikian G, Zynger DL. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management? *Hum Pathol* 2017; **62**: 215-221 [PMID: [28041972](#) DOI: [10.1016/j.humpath.2016.12.019](#)]
 - 21 **Niikura N**, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. *Ann Oncol* 2016; **27**: 480-487 [PMID: [26704052](#) DOI: [10.1093/annonc/mdv611](#)]
 - 22 **Gahlaut R**, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, Perren T, Dodwell D, Lansdown M, Shaaban AM. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. *Eur J Cancer* 2016; **60**: 40-48 [PMID: [27062316](#) DOI: [10.1016/j.ejca.2016.03.006](#)]
 - 23 **Lim SK**, Lee MH, Park IH, You JY, Nam BH, Kim BN, Ro J, Lee KS, Jung SY, Kwon YM, Lee ES. Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. *Cancer Res Treat* 2016; **48**: 133-141 [PMID: [25865655](#) DOI: [10.4143/crt.2014.262](#)]
 - 24 **Zhou X**, Zhang J, Yun H, Shi R, Wang Y, Wang W, Lagercrantz SB, Mu K. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. *Oncotarget* 2015; **6**: 36894-36902 [PMID: [26384297](#) DOI: [10.18632/oncotarget.5050](#)]
 - 25 **Jin X**, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. *Oncotarget* 2015; **6**: 9600-9611 [PMID: [25826079](#) DOI: [10.18632/oncotarget.3292](#)]
 - 26 **Tan QX**, Qin QH, Yang WP, Lian B, Wei CY. Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. *Int J Clin Exp Pathol* 2014; **7**: 4086-4094 [PMID: [25120787](#)]
 - 27 **Yang YF**, Liao YY, Li LQ, Xie SR, Xie YF, Peng NF. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. *Pathol Res Pract* 2013; **209**: 797-802 [PMID: [24183366](#) DOI: [10.1016/j.prp.2013.08.012](#)]
 - 28 **Cockburn A**, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, Rumnong Sarode V. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. *Hum Pathol* 2014; **45**: 249-258 [PMID: [24289969](#) DOI: [10.1016/j.humpath.2013.09.002](#)]
 - 29 **Lee HC**, Ko H, Seol H, Noh DY, Han W, Kim TY, Im SA, Park IA. Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response. *J Breast Cancer* 2013; **16**: 395-403 [PMID: [24454461](#) DOI: [10.4048/jbc.2013.16.4.395](#)]
 - 30 **Dede DS**, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. *J BUON* 2013; **18**: 366-371 [PMID: [23818347](#)]
 - 31 **Kumaki N**, Umemura S, Tang X, Saito Y, Suzuki Y, Tokuda Y. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67. *Breast Cancer* 2011; **18**: 98-102 [PMID: [21290265](#) DOI: [10.1007/s12282-010-0238-1](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

